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One Size Does Not Fit All*David E. Kandzari, MDA s a condition of approval for the Endeavorzotarolimus-eluting stent (ZES) (MedtronicCardioVascular, Santa Rosa, California) in
February 2008, the U.S. Food and Drug Administra-
tion considered, “the investigation of the optimal
duration of dual antiplatelet therapy as a drug-
eluting stent(s) (DES) class effect” (1). Despite this
perspective, early comparative studies with ZES sug-
gested that all stents were not equal. As the ﬁrst
drug-eluting stent (DES) compared in separate ran-
domized trials against both bare-metal stent(s)
(BMS) and ﬁrst-generation sirolimus-eluting stent(s)
(SES) and paclitaxel-eluting stent(s) (PES), ZES were
associated with angiographic and clinical outcomes
that were, at best, superior to BMS, but at worst,
angiographically inferior and marginally similar in
clinical efﬁcacy to commercially available DES. ZES
appeared to be a less effective therapy, and there
was little evidence to support any differentiating
signal of safety.
As in the real-world care of patients, life continues
beyond ascertainment of primary endpoints in clin-
ical trials. Long-term follow-up and accrual of a larger
patient population and events have resulted in a
more complete understanding of the clinical perfor-
mance of ZES. Through 5 years of follow-up in
the modest-sized ENDEAVOR III (A Randomized
Controlled Trial of the Medtronic Endeavor Drug*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Piedmont Heart Institute, Atlanta, Georgia. Dr. Kandzari has
received research/grant support from Abbott Vascular, Biotronik, Boston
Scientiﬁc Corporation, Medinol, and Medtronic CardioVascular; and
consulting honoraria from Boston Scientiﬁc Corporation, Medtronic
CardioVascular, and Micell Technologies.[ABT-578] Eluting Coronary Stent System Versus the
Cypher Sirolimus-Eluting Coronary Stent System in
De Novo Native Coronary Artery Lesions) trial (2),
outcomes of cardiac death and myocardial infarction
(MI) were signiﬁcantly lower, and rates of repeat
revascularization were similar with ZES compared
with SES. Between the 9-month primary endpoint
and 5 years, progression of major events was more
than twice as common with SES versus ZES. Similarly,
in a larger comparison with PES, cardiac death and
MI, in addition to very late (>1 year) stent thrombosis,
were signiﬁcantly less frequent with ZES at 5 years
(3). Altogether, in a pooled analysis of registration
trials that compared ZES with ﬁrst-generation DES
(4), despite higher repeat revascularization with ZES
in the ﬁrst year, rates of cardiac death and MI, target
revascularization, and stent thrombosis were signi-
ﬁcantly lower with ZES between 1 and 5 years post-
revascularization. Thus, in comparison with late
lumen loss or angiographic restenosis, more con-
temporary analyses directed toward patient-oriented
outcomes identiﬁed emerging differences in late
efﬁcacy and safety events that were less closely
linked to early surrogates. A pattern of clinical sta-
bility emerged with ZES, which was considered the
dark horse of DES—not leading the race early, but
ﬁnishing strongly.
Additional comparative studies afﬁrmed previous
clinical observations. Through intermediate follow-
up, the SORT OUT III (Comparison of Zotarolimus-
Eluting Stents and Sirolimus-Eluting Stents in
Patients With Coronary Artery Disease) trial (5)
demonstrated higher repeat revascularization, and
modest, but signiﬁcantly higher, adverse events with
ZES compared with SES, prompting 1 of the study’s
investigators to claim “we took it (ZES) off the shelf”
(6). However, at 5 years, such differences no longer
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817persisted, and between 1 and 5 years, ZES were
associated with signiﬁcantly lower stent thrombosis
(1 of 1,162 events with ZES vs. 21 of 1,170 events with
SES) and target lesion revascularization (7). Similarly,
the PROTECT (Patient Related Outcomes with
Endeavor versus Cypher Stenting Trial) study, the
largest randomized trial that was statistically pow-
ered to compare stent thrombosis, also showed
signiﬁcantly lower cumulative stent thrombosis
through 5 years, which was principally driven by
lower late term (>1 year) events (8).
These clinical observations were further supported
by independent mechanistic studies. ZES are charac-
terized by a phosphorylcholine polymer, which
structurally mimics the lipid component of a natural
cell membrane. Compared with alternative DES, the
polymer allows more rapid dissolution of zotarolimus
(95% within 14 days of implantation), although mea-
surable tissue concentrations of the antiproliferative
drug persist beyond 30 days. Accordingly, ZES are
more permissive of early neointimal hyperplasia, and
translational studies have indicated accelerated
vessel healing, which has been demonstrated by more
rapid and complete strut coverage, less malap-
position, and early recovery of endothelial vasomotor
function. These are phenotypical features of BMS, but
not of early-generation DES (9,10).
Trial results, translational science, and experience
from clinical practice motivated additional study into
the relationship among ZES, the duration of dual
antiplatelet therapy (DAPT), and ischemic events. In
a pooled analysis of patients treated with ZES,
6 months versus 2 years of DAPT were associated
with similar, favorably low occurrences of late-term
thrombotic events through 3 years of follow-up (11).
Additional trials that compared DAPT durations
following ZES revascularization of 3 months versus 12
months also demonstrated no increased likelihood of
ischemic events (12,13).SEE PAGE 805In this issue of the Journal, the ZEUS (Zotarolimus-
eluting Endeavor sprint stent in Uncertain DES can-
didates) study investigators (14) further tested the
boundaries of abbreviated antiplatelet therapy and
ZES safety in a patient population that is routinely
excluded from DES trials and challenged by DAPT
adherence. In 1,606 randomized patients character-
ized as uncertain DES candidates on the basis of
thrombotic, bleeding, and restenosis risk factors, the
1-year occurrence of composite major adverse events
was signiﬁcantly lower with ZES compared with
BMS revascularization (17.5% vs. 22.1%; p ¼ 0.011).
This difference was driven by both lower clinicalrestenosis and MI. Unexpectedly, and despite a me-
dian DAPT duration of only 32 days, stent thrombosis
was also signiﬁcantly lower among ZES-treated pa-
tients (2.0% vs. 4.1%; p ¼ 0.019). The stent throm-
bosis rates were notably higher than in more
conventional trials and in less heterogeneous pop-
ulations. The ZEUS trial was also not statistically
designed to deﬁnitively compare individual end-
points, and it is unclear what proportion of patients
with MI had events that were related to stents. Spe-
ciﬁcally, the contribution of stent thrombosis and
restenosis-related ischemic events to the higher MI
rate with BMS is uncertain. Unlike most studies in
which the comparative effectiveness of ZES versus
other DES emerged over the late term, differences
from BMS were more readily apparent in the ﬁrst year
of the ZEUS study.
More broadly, the conclusions from the ZEUS trial
address 2 clinically relevant issues. First, the study
introduced a method by which practitioners might
tailor antithrombotic and stent therapy based on
individual assessment of risk and beneﬁt. Recog-
nizing that societal guidelines: 1) do not provide
treatment options for this unique, but commonly
encounter such a patient population; and 2) are based
more on opinion and inferential evidence (15), clinical
decision making has represented more of the art of
medicine than the science of medicine. On the basis
of existing evidence, it is fair to suppose that there
is no optimal duration of DAPT that applies to all
patients. The ZEUS study instead informs treatment
decisions for patients underrepresented by evidence-
based medicine, and whose clinical picture cannot be
painted with broad and common strokes.
Second, the trial results challenge whether
there remains a clinical purpose for BMS. Although
uncommon, stent thrombosis is associated with
considerable risk of MI and mortality, regardless of
timing or stent type. Reports with early-generation
DES correlated “premature” antiplatelet therapy
discontinuation with the risk of stent thrombosis (16),
and other observations indicated clinical beneﬁt with
long-term DAPT, without reporting stent thrombosis
(17). Citing these data, DES are assigned a class III
recommendation of harm for patients who may not
adhere to prolonged DAPT or in whom compliance
cannot be conﬁrmed before revascularization (18),
which is, in many ways, the exact patient population
intended for this study. However, amidst the atten-
tion to DES, DAPT adherence, and stent thrombosis, a
blind eye may have been turned toward the conse-
quences of restenosis and a false reassurance of
guideline-advocated 1-month DAPT for BMS. Delayed
stent thrombosis does occur with BMS, and ischemic
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818events attributed to bare-metal restenosis have
been described (19,20). In the recent DAPT (Dual-
Antiplatelet Therapy) trial, cumulative stent throm-
bosis through 33 months was signiﬁcantly higher with
BMS than DES, and the composite outcome of death,
MI, and stroke also tended to be lower in the DES
cohort (21). Although statistically underpowered, the
relative beneﬁt with long-term (30 months) DAPT
versus 12 months of DAPT in BMS patients appeared
similar to that observed with DES.
In the absence of well-conducted, randomized
trials, assumptions as to whether similar safety and
greater efﬁcacy in similar patients will translate to
other commercially available DES will be common-
place. For example, recent European guidelines
advise <6 months of DAPT following DES implanta-
tion for patients with bleeding risk, although this
recommendation (Class IIb, Level of Evidence: A) is
on the basis of 2 studies made exclusively with ZES
(22). Limited, nonrandomized data with more con-
temporary DES suggest a low risk of ischemic events
with DAPT interruption following periods as brief as
1 month post-revascularization (23). Large, aggregate
data from pooled trials also suggest the risk of stent
thrombosis with newer generation DES could be even
lower than for BMS (24). In a large survey of patients
who underwent noncardiac surgery following stentrevascularization, the occurrence of ischemic events
was signiﬁcantly higher with BMS compared with
unselected DES (25). Finally, the safety of stents
incorporating bioresorbable materials is intuitive, but
inconsistently proven, and a clinical study with these
stents and only 1 month of DAPT is ongoing (26). Still,
in the absence of well conducted and randomized
trials, such speculation will remain guesswork.
In the endeavor to design studies that more care-
fully represent routine clinical practice, the ZEUS trial
is as “real-world” as can be. In contemporary practice,
BMS represent approximately 10% to 30% of world-
wide total stent use. The ZEUS trial tested a very
common dilemma related to stent selection, con-
tested more generalized guideline recommendations,
and offered a model for treatment decisions on the
basis of individualized risk and/or beneﬁt assess-
ment, rather than a “one size ﬁts all” strategy. Amidst
the enthusiasm for devices and pharmacotherapies
for tomorrow’s interventions, practical and thought-
fully designed trials that inform today’s practice are
welcomed.
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